CAMBRIDGE, Mass., Oct. 21 /PRNewswire/ -- Sermo (http://www.sermo.com), the largest online community for physicians, today announced a free Sermo Report titled, "Physician Participation in the ESA REMS Program." The report covers physician perceptions and participation rates in the FDA-required Erythropoiesis-Stimulating Agents (ESAs) risk evaluation and mitigation strategy (REMS) program.
According to the results, 83% of Hematologists/Oncologists view the ESA REMS program as a barrier to utilization of associated drugs. As one HemOnc noted, "The purpose of REMS is to reduce patient access to ESAs, or more accurately to reduce their demand by scaring them away, and also by limiting the supply of physicians who are willing to put up with the work for little return."
This free Sermo Report polled 60 physicians who also participated in an online discussion regarding treatment strategies for renal associated anemia.
Highlights from the report include:
The full reports includes:
Physicians are required to complete the ESA REMS program by March 2011 to be eligible to prescribe these products. The goals of the REMS for ESAs are:
Erythropoiesis Stimulating Agents include products from Amgen and Centocor Ortho Biotech Products, L.P.
To download report results, visit sermo.com/client.
About Sermo Reports
Sermo Reports solicit perceptions and opinions from physicians about new drugs, devices, treatments, and trends. Data for Sermo Reports is gathered through Sermo Posts, which allow physicians to participate in a poll and comment on the topic. All physicians on Sermo are verified and credentialed.
Sermo is the largest online physician community, where over 115,000 practicing physicians discuss a wide range of issues from clinical cases to advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into unsolicited, peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For information, visit www.sermo.com/clients.
Copyright©2010 PR Newswire.
All rights reserved